These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 15160342

  • 1. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
    Høgdall EV, Ryan A, Kjaer SK, Blaakaer J, Christensen L, Bock JE, Glud E, Jacobs IJ, Høgdall CK.
    Cancer; 2004 Jun 01; 100(11):2387-95. PubMed ID: 15160342
    [Abstract] [Full Text] [Related]

  • 2. P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study.
    Høgdall EV, Kjaer SK, Blaakaer J, Christensen L, Glud E, Vuust J, Høgdall CK.
    Gynecol Oncol; 2006 Jan 01; 100(1):76-82. PubMed ID: 16183105
    [Abstract] [Full Text] [Related]

  • 3. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
    Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Nørgaard-Pedersen B, Høgdall CK.
    Cancer; 2003 Jul 01; 98(1):66-73. PubMed ID: 12833457
    [Abstract] [Full Text] [Related]

  • 4. Loss of heterozygosity at chromosome 9q22-31 is a frequent and early event in ovarian tumors.
    Byrom J, Mudaliar V, Redman CW, Jones P, Strange RC, Hoban PR.
    Int J Oncol; 2004 May 01; 24(5):1271-7. PubMed ID: 15067351
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV, Christensen L, Høgdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK.
    Oncol Rep; 2007 Nov 01; 18(5):1051-9. PubMed ID: 17914554
    [Abstract] [Full Text] [Related]

  • 6. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD, Høgdall CK, Kjaer SK, Christensen L, Blaakaer J, Bock JE, Glud E, Høyer-Hansen G, Ring-Larsen H, Høgdall EV.
    Anticancer Res; 2004 Nov 01; 24(3b):1981-5. PubMed ID: 15274388
    [Abstract] [Full Text] [Related]

  • 7. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, Young RC, Gynecologic Oncology Group.
    Cancer; 2008 May 15; 112(10):2202-10. PubMed ID: 18348296
    [Abstract] [Full Text] [Related]

  • 8. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer.
    Bignone PA, Lee KY, Liu Y, Emilion G, Finch J, Soosay AE, Charnock FM, Beck S, Dunham I, Mungall AJ, Ganesan TS.
    Oncogene; 2007 Feb 01; 26(5):683-700. PubMed ID: 16878154
    [Abstract] [Full Text] [Related]

  • 9. Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas.
    Choi C, Cho S, Horikawa I, Berchuck A, Wang N, Cedrone E, Jhung SW, Lee JB, Kerr J, Chenevix-Trench G, Kim S, Barrett JC, Koi M.
    Genes Chromosomes Cancer; 1997 Nov 01; 20(3):234-42. PubMed ID: 9365830
    [Abstract] [Full Text] [Related]

  • 10. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP, Gynecologic Oncology Group.
    J Clin Oncol; 2008 Jan 01; 26(1):83-9. PubMed ID: 18025437
    [Abstract] [Full Text] [Related]

  • 11. Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer.
    Gamzatova Z, Villabona L, Dahlgren L, Dalianis T, Nillson B, Bergfeldt K, Masucci GV.
    Gynecol Oncol; 2006 Oct 01; 103(1):145-50. PubMed ID: 16542716
    [Abstract] [Full Text] [Related]

  • 12. [Loss of heterozygosity at chromosome 3p14, 25 in serum DNA from ovarian cancer patients].
    Zhang H, Li Z, Chen M, Zhang G, Xu K.
    Zhonghua Fu Chan Ke Za Zhi; 2002 May 01; 37(5):298-300. PubMed ID: 12133406
    [Abstract] [Full Text] [Related]

  • 13. Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin.
    Ueno Y, Enomoto T, Otsuki Y, Sugita N, Nakashima R, Yoshino K, Kuragaki C, Ueda Y, Aki T, Ikegami H, Yamazaki M, Ito K, Nagamatsu M, Nishizaki T, Asada M, Kameda T, Wakimoto A, Mizutani T, Yamada T, Murata Y.
    Cancer Lett; 2006 Sep 28; 241(2):289-300. PubMed ID: 16459017
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study.
    Høgdall EV, Kjaer SK, Glud E, Christensen L, Blaakaer J, Vuust J, Bock JE, Norgaard-Pedersen B, Hogdall CK.
    Anticancer Res; 2003 Sep 28; 23(4):3397-404. PubMed ID: 12926080
    [Abstract] [Full Text] [Related]

  • 15. CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
    Sillanpää S, Anttila MA, Voutilainen K, Tammi RH, Tammi MI, Saarikoski SV, Kosma VM.
    Clin Cancer Res; 2003 Nov 01; 9(14):5318-24. PubMed ID: 14614016
    [Abstract] [Full Text] [Related]

  • 16. [Assessment of prognostic factors in common ovarian tumors of varying malignancy].
    Demeter A, Várkonyi T, Csapó Z, Szánthó A, Oláh J, Papp Z.
    Magy Onkol; 2004 Nov 01; 48(3):259-65. PubMed ID: 15520877
    [Abstract] [Full Text] [Related]

  • 17. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
    Torng PL, Mao TL, Chan WY, Huang SC, Lin CT.
    Gynecol Oncol; 2004 Feb 01; 92(2):559-67. PubMed ID: 14766248
    [Abstract] [Full Text] [Related]

  • 18. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
    Shigemasa K, Tian X, Gu L, Tanimoto H, Underwood LJ, O'Brien TJ, Ohama K.
    Oncol Rep; 2004 Jun 01; 11(6):1153-9. PubMed ID: 15138549
    [Abstract] [Full Text] [Related]

  • 19. Serum tetranectin is a significant prognostic marker in ovarian cancer patients.
    Begum FD, Høgdall E, Christensen IJ, Kjaer SK, Blaakaer J, Christensen L, Høgdall C.
    Acta Obstet Gynecol Scand; 2010 Jun 01; 89(2):190-8. PubMed ID: 20121334
    [Abstract] [Full Text] [Related]

  • 20. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
    Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Christensen IJ, Gayther S, Jacobs IJ, Høgdall CK.
    Gynecol Oncol; 2007 Aug 01; 106(2):318-24. PubMed ID: 17540436
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.